Sterling, Lulu R.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 807

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 432

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Bhatt, D. L., Bays, H. E., Miller, M., Cain, J. E., Wasilewska, K., Andrawis, N. S., Parli, T., Feng, S., Sterling, L., Tseng, L., et al. (2023) · Nature Medicine

Lipid metabolism and disordersFibroblast Growth Factor Research

Cited by 121

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial

Lalwani, N. D., Hanselman, J. C., MacDougall, D. E., Sterling, L. R., & Cramer, C. T. (2019) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 72

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Rubino, J., MacDougall, D. E., Sterling, L. R., Kelly, S. E., McKenney, J. M., & Lalwani, N. D. (2021) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 69